Sigumir Protocol
Dosing & Research
Last Updated: September 4, 2026
Cardiovascular support research, Blood-pressure and vascular aging models, Microcirculation studies, Cardiac resilience
Half-Life
Variable (complex)
Administration
Oral
Frequency
1-2 times daily
How It Works
- Cardiovascular support research
- Blood-pressure and vascular aging models
- Microcirculation studies
- Cardiac resilience
Dosing Structure
Dose
20–40 mg
Frequency
1-2 times daily
Notes
Typically Administered As Defined Courses (10–20 Days) Repeated 1–2x Per Year, Rather Than Continuous Daily Dosing. Based On Khavinson Institute And Associated Russian Clinical Research.
Example Protocols
Dose: 20–40 mg
Frequency: 1-2 times daily
Duration: 30 Days
Off Period: Not listed
Find Research Grade Sigumir
Recommended vendors for sourcing research-grade material. PeptaBase does not sell peptides directly.
Vendor One Research Labs
COA VerifiedThird-party COA-verified research peptides with published batch testing.
Source Coming SoonVendor Two Sciences
Purity TestedUS-based research compound supplier with independent purity testing.
Source Coming SoonVendor Three Peptide Co.
Bulk research peptide sourcing with batch-level documentation.
Source Coming SoonProtocol Notes
•
Typically administered as defined courses (10–20 days) repeated 1–2x per year, rather than continuous daily dosing.
•
Based on Khavinson Institute and associated Russian clinical research.
Research & Studies
Loading citations…
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.